Type1Cure tracks research, trials, devices, safety alerts, company movement, and community signals, then turns them into evidence-labeled briefings a parent can act on.
This launch version ships with curated seed intelligence. The ingestion pipeline is documented and staged for PubMed, ClinicalTrials.gov, FDA, RSS/news, and compliant social/video sources.
Clinical trials, biotech filings, peer-reviewed papers
The highest-value watchlist combines islet or stem-cell derived beta cells, encapsulation, immune modulation, and durable insulin independence endpoints.
FDA, device makers, ADA technology updates
Closed-loop systems, CGM accuracy, interoperability, algorithm updates, infusion-set reliability, and recall notices deserve daily monitoring.
ClinicalTrials.gov, TrialNet, academic centers
Recruiting trials can be filtered by age, geography, disease stage, intervention class, and travel burden without storing sensitive profiles by default.
YouTube, creator feeds, podcasts, community submissions
Creator posts can surface practical lived experience and early buzz, but must be separated from clinical claims and sponsor influence.
Cure news has to be handled carefully. The product ranks items by evidence class, patient relevance, novelty, and actionability, then sends high-risk claims through human review.
View trust controlsEvery item is marked as peer reviewed, preprint, clinical trial, regulatory, company PR, news, social, or anecdotal.
No miracle language, no supplement hype, no diagnosis advice, and no pay-to-rank editorial placement.
Source pulls use retries, source checksums, canonical IDs, and duplicate protection before publication.
High-impact items, safety alerts, trial eligibility, and sponsor-sensitive content enter an editorial queue.
The source registry is treated as a product surface: every feed needs a method, cadence, trust tier, license/terms note, failure behavior, and a reason it matters to families.
DOI/NCT dedupe, phase tagging, human-vs-animal labeling, and plain-English evidence summaries.
Age, location, recruiting status, intervention class, endpoint, and contact changes tracked over time.
CGM, pump, infusion, insulin, glucagon, app, and interoperability alerts are escalated above news.
Company claims are labeled as PR until independently supported by clinical or regulatory evidence.
Official APIs, embeds, creator permission, and community submissions keep platform use compliant.
Commercial movement is separated from medical recommendations and ranked by patient relevance.
If FDA, MedWatch, or a manufacturer issues a relevant CGM, pump, app, insulin, or glucagon alert, it should bypass the normal feed and hit the family alert lane first.
Sensor reliability, app outages, calibration warnings.
Infusion sets, algorithm behavior, dosing interruption.
Insulin, glucagon, shortages, labeling changes.
Practical family actions, backup-plan language.
YouTube, podcasts, creator posts, parent forums, and lived experience can reveal what matters in real life. The site captures that signal while labeling anecdote, sponsorship, and platform limits clearly.
The first social release should use YouTube API, podcast RSS, manual creator watchlists, embeds where permitted, and community submissions. TikTok, Instagram, and Facebook require official APIs, permissions, or paid listening partners.
The revenue plan is designed to fund serious monitoring without letting advertisers, affiliates, or trial sponsors distort coverage.
Parents, advocates, clinicians, investors
Free weekly digest plus paid daily alerts, trial watches, and research briefs.
Editorial coverage never depends on payment from companies being covered.
Device, education, insurance navigation, nonprofit, and event partners
Clearly labeled newsletter, webinar, and event sponsorships.
Sponsors get reach, not editorial control, claims review, or hidden native ads.
Families buying practical T1D gear
Disclosed affiliate links for bags, patches, travel gear, books, and low supplies.
No affiliate influence on safety coverage, rankings, or medical claims.
Families looking for legitimate study opportunities
Privacy-minimal alerts and optional concierge matching.
No sale of health profiles; users control what is stored and shared.
The build sequence gets the public brand live first, then adds ingestion, review, alerts, premium intelligence, and partnerships without rewriting the foundation.